ELITEK (rasburicase)
HYPERURICEMIA AGENTS (NON-URICOSURIC) · HYPERURICEMIA DUE TO CANCER THERAPY
Sanofi-Aventis U.S.
Drug class
Hyperuricemia Agents (non-uricosuric)
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance. Read more about Hyperuricemia Agents (non-uricosuric)
58 drugs in this class 52 manufacturers
Drugs in Hyperuricemia Agents (non-uricosuric)
ULORIC (febuxostat)
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK
Takeda Pharmaceuticals America
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
Mylan Pharmaceuticals
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
NORTHSTAR RX LL
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
DR.REDDY'S LAB
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
AHP
ALOPRIM (allopurinol sodium)
HYPERURICEMIA AGENTS (NON-URICOSURIC) · HYPERURICEMIA DUE TO CANCER THERAPY
MYLAN INSTITUTI
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
SUN PHARMACEUTI
ALLOPURINOL
HYPERURICEMIA AGENTS (NON-URICOSURIC) · PREVENTION OF ACUTE GOUT ATTACK ·+4
INGENUS PHARMAC
Filter & compare in the drug finder →
Opens the drug finder with Hyperuricemia Agents (non-uricosuric) preselected. Add indication or manufacturer filters there.
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance.
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin.
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria.
-
fda.gov
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
-
fda.gov
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
connectrx.com
Hyperuricemia Agents (non-uricosuric) is a clinical and compendial classification grouping medications that reduce serum uric acid concentrations through mechanisms other than increasing renal uric acid clearance
-
singlecare.com
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
connectrx.com
Rather than promoting urinary excretion via renal transporter inhibition, these agents primarily function by inhibiting uric acid synthesis through xanthine oxidase inhibition or by enzymatically degrading existing circulating urate into soluble allantoin
-
fda.gov
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
-
drugs.com
The class is therapeutically utilized in the management and prevention of chronic gout, hyperuricemia associated with cancer chemotherapy or tumor lysis syndrome, and recurrent calcium oxalate nephrolithiasis secondary to hyperuricosuria
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.